Medtronic
MDT
Market cap $115B

89.73 USD

-0.19

0.21%

At close Jul 14, 4:00 PM EDT

After hours

89.73

+0.00

0.00%

1 day

-0.21%

5 days

2.48%

1 month

2.06%

3 months

6.54%

6 months

5.26%

Year to date

11.85%

1 year

16.41%

5 years

-5.20%

10 years

18.24%

About: One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

Employees: 95,000

Healthcare Medical Devices

0

Funds holding %

of 7,315 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

64% more first-time investments, than exits

New positions opened: 205 | Existing positions closed: 125

39% more funds holding in top 10

Funds holding in top 10: 31 [Q4 2024] → 43 (+12) [Q1 2025]

17% more repeat investments, than reductions

Existing positions increased: 923 | Existing positions reduced: 787

14% more capital invested

Capital invested by funds: $85.1B [Q4 2024] → $96.9B (+$11.9B) [Q1 2025]

2% more funds holding

Funds holding: 2,090 [Q4 2024] → 2,128 (+38) [Q1 2025]

1% more call options, than puts

Call options by funds: $1.05B | Put options by funds: $1.04B

0.18% less ownership

Funds ownership: 83.02% [Q4 2024] → 82.84% (-0.18%) [Q1 2025]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$92

3%

upside

Avg. target

$101

13%

upside

High target

$110

23%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

Citigroup Joanne Wuensch	10%upside $99	Buy Maintained	9 Jul 2025
Evercore ISI Group Vijay Kumar	18%upside $106	Outperform Maintained	8 Jul 2025
Leerink Partners Mike Kratky	23%upside $110	Outperform Initiated	16 Jun 2025
Mizuho Anthony Petrone	9%upside $98	Outperform Maintained	22 May 2025
RBC Capital Shagun Singh	13%upside $101	Outperform Maintained	22 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 17 articles about MDT published over the past 30 days

The Motley Fool

The Best High Yield Medical Device Stock to Invest $1,000 in Right Now

One of the good things about the healthcare sector is that most medical care isn't optional. This is the foundation behind the sector, but on that foundation sits the growth opportunity that comes with medical advances.

The Best High Yield Medical Device Stock to Invest $1,000 in Right Now

The Motley Fool

What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill

Dividend investing, like most things in life, can be rewarding if done correctly or a headache if you make crucial mistakes. The key to dividend investing is to pick the right types of dividend stocks.

What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill

The Motley Fool

1 No-Brainer Dividend Stock to Buy Now and Hold Forever

Publicly traded corporations are under no obligation to pay dividends. Among those that do, many are rather subpar in the exercise, particularly with how often they raise their payouts.

1 No-Brainer Dividend Stock to Buy Now and Hold Forever

24/7 Wall Street

BofA Securities Top Q3 Stocks Picks Feature 4 Incredible Dividend Ideas

Dividend stocks are a favorite among investors for good reason.

BofA Securities Top Q3 Stocks Picks Feature 4 Incredible Dividend Ideas

Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

GALWAY, Ireland , July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.

Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

3 Safe Buy-and-Hold Dividend Stocks With Strong Balance Sheets

Dividend yield is a commonly used metric for finding dividend stocks to buy and hold. The dividend yield is the amount of a company's dividend as a percentage of its stock price.

3 Safe Buy-and-Hold Dividend Stocks With Strong Balance Sheets

Zacks Investment Research

Medtronic (MDT) Beats Stock Market Upswing: What Investors Need to Know

Medtronic (MDT) closed the most recent trading day at $87.17, moving +1.34% from the previous trading session.

Medtronic (MDT) Beats Stock Market Upswing: What Investors Need to Know

Medtronic: Margin Inflection With Diabetes Spin - Key Drivers

Initiate Medtronic with Strong Buy, $161 PT, citing a structural margin inflection from Diabetes spin-off and robust innovation pipeline (120+ approvals). Street underestimates FY27 margin/EPS upside from Diabetes separation and operating leverage in Cardiac & Structural Heart—key drivers for re-rating. Valuation at 26x FY27E EPS is conservative versus peers; scenario analysis shows risk skewed to the upside, as margin catalysts execute.

Medtronic: Margin Inflection With Diabetes Spin - Key Drivers

Medtronic: Eyes On The Pipeline And Spin, Shares Still Cheap

I reiterate my buy rating on Medtronic, driven by solid fundamentals and an attractive valuation, despite less upside versus prior estimates. Medtronic continues to deliver steady revenue growth, robust free cash flow, and a 48-year dividend growth streak, even as sector sentiment weakens. Key risks include competitive pressures, margin threats in Diabetes and CAS, and macro headwinds like tariffs, requiring prudent management execution.

Medtronic: Eyes On The Pipeline And Spin, Shares Still Cheap

Zacks Investment Research

BSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?

Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). Two prominent companies with a strong foothold in this space are Boston Scientific BSX and Medtronic MDT.

BSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?

See News Rankings

Charts implemented using Lightweight Charts™